Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded

Hemamali Samaratunga; Brett Delahunt; Lars Egevad; John R Srigley; Athanase Billis; David G Bostwick; Philippe Camparo; Liang Cheng; David Clouston; James Denham; Bungo Furusato; Arndt Hartmann; Laura Jufe; James Kench; Diane N Kenwright; Glen Kristiansen; Katia R M Leite; Gregory T MacLennan; Jennifer Merrimen; Holger Moch; Jon Oxley; Chin-Chen Pan; Gladell Paner; Jae Ro; Isabell A M Sesterhenn; Jonathan Shanks; Michelle Thunders; Toyonori Tsuzuki; Thomas Wheeler; John W Yaxley; Murali Varma

doi:10.1016/j.pathol.2019.11.001

Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded

Pathology. 2020 Feb;52(2):192-196. doi: 10.1016/j.pathol.2019.11.001. Epub 2019 Dec 14.

Authors

Hemamali Samaratunga¹, Brett Delahunt², Lars Egevad³, John R Srigley⁴, Athanase Billis⁵, David G Bostwick⁶, Philippe Camparo⁷, Liang Cheng⁸, David Clouston⁹, James Denham¹⁰, Bungo Furusato¹¹, Arndt Hartmann¹², Laura Jufe¹³, James Kench¹⁴, Diane N Kenwright¹⁵, Glen Kristiansen¹⁶, Katia R M Leite¹⁷, Gregory T MacLennan¹⁸, Jennifer Merrimen¹⁹, Holger Moch²⁰, Jon Oxley²¹, Chin-Chen Pan²², Gladell Paner²³, Jae Ro²⁴, Isabell A M Sesterhenn²⁵, Jonathan Shanks²⁶, Michelle Thunders¹⁵, Toyonori Tsuzuki²⁷, Thomas Wheeler²⁸, John W Yaxley²⁹, Murali Varma³⁰

Affiliations

¹ Aquesta Uropathology and University of Queensland, Brisbane, Qld, Australia.
² Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand. Electronic address: brett.delahunt@otago.ac.nz.
³ Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
⁴ Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
⁵ Department of Anatomic Pathology, School of Medical Sciences, State University of Campinas (Unicamp) Campinas, SP, Brazil.
⁶ Bostwick Laboratories, Orlando, FL, USA.
⁷ Department of Pathology, Centre de Pathologie Amiens, Amiens, France.
⁸ Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
⁹ TissuPath, Mount Waverley, Vic, Australia.
¹⁰ School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
¹¹ Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences and Cancer Genomics Unit, Clinical Genomics Center, Nagasaki University Hospital, Sakamoto, Nagasaki, Japan.
¹² Institute of Pathology, University Erlangen-Nürnberg, Erlangen, Germany.
¹³ Servicio de Anatomía Patológica. Hospital General de Agudos J.M. Ramos Mejía, Ciudad Autónoma de Buenos Aires, Argentina.
¹⁴ Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and Central Clinical School, University of Sydney, Sydney, NSW, Australia.
¹⁵ Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand.
¹⁶ Institue of Pathology, Reference Centre for Uropathology, University Hospital Bonn, Bonn, Germany.
¹⁷ Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil.
¹⁸ Department of Pathology and Urology, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
¹⁹ Division of Anatomical Pathology, QEII Health Sciences Centre, Halifax, NS, Canada.
²⁰ University and University Hospital Zurich, Department of Pathology and Molecular Pathology, Zurich, Switzerland.
²¹ North Bristol NHS Trust, Bristol, UK.
²² Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan.
²³ Departments of Pathology and Surgery (Section of Urology) University of Chicago, Chicago, IL, USA.
²⁴ Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Medical College of Cornell University, Houston, TX, USA.
²⁵ Joint Pathology Center, Silver Spring, MD, USA.
²⁶ Department of Histopathology, The Christie NHS Foundation Trust, Manchester, UK.
²⁷ Department of Surgical Pathology, Aichi Medical University, School of Medicine, Nagakute, Japan.
²⁸ Department of Pathology and Laboratory Medicine, Baylor St. Luke's Medical Center and Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.
²⁹ Department of Medicine, University of Queensland, Wesley Urology Clinic, Royal Brisbane and Women's Hospital, Brisbane, Australia.
³⁰ Department of Cellular Pathology, University Hospital of Wales, Cardiff, UK.

PMID: 31843189
DOI: 10.1016/j.pathol.2019.11.001

Abstract

Infiltration of the prostatic ducts by prostatic adenocarcinoma occurs relatively frequently, being most commonly associated with high grade disease. It is now recognised that intraductal carcinoma of the prostate (IDCP) has an associated poor prognosis and this is reflected in its histological, molecular and immunohistochemical features. The current recommendation of the World Health Organization is that IDCP not be taken into consideration when grading prostate adenocarcinoma. It is apparent that Gleason did not differentiate between IDCP and stromal invasive carcinoma when developing and validating his grading system, and recent studies suggest that the incorporation of IDCP grading into the overall grading of the specimen provides additional prognostic information.

Keywords: ISUP grade; Prostate adenocarcinoma; intraductal carcinoma of prostate; prognosis.

Publication types

Review

MeSH terms

Carcinoma, Ductal / pathology*
Humans
Male
Neoplasm Grading*
Prostatic Neoplasms / pathology*